Current Events and General Interest Bits & Pieces Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Current Events and General Interest Bits & Pieces

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Win Smith who started this subject	3/19/2003 5:10:05 AM
From: FaultLine	of 603

Biotech developing anthrax drug money.cnn.com Results from pre-clinical studies showed that a single dose of ABthrax boosts chances of survival. March 18, 2003: 7:11 AM EST ROCKVILLE, Md. (Reuters) - Human Genome Sciences Inc., a U.S. company that makes gene-based drugs, said Tuesday it was developing an immune system drug that could help thwart the effects of anthrax exposure. With a U.S.-led war against Iraq expected within days, fears of Iraq unleashing weapons of mass destruction are mounting. Experts said Monday an anthrax attack on a city the size of New York could leave more than 100,000 dead within days. Five people died after receiving anthrax-tainted letters in 2001. Human Genome, based in Rockville, Md., said it plans to develop ABthrax for use as a prophylactic and therapeutic drug to prevent and treat anthrax infections. It said results from pre-clinical studies showed that a single dose of ABthrax administered prophylactically significantly boosts survival in rabbits and non-human primates exposed by inhaling lethal doses of anthrax spores. There was an absence of bacteria in the blood of all ABthrax-treated animals that survived, it said in a statement. ABthrax prevents the anthrax toxins from entering and killing cells by blocking the binding of protective antigen to cell surfaces, the company added. Human Genome said it plans to seek approval soon from the U.S. Food and Drug Administration to assess how the drug is tolerated by healthy adults, even though it would not be ethical to do this through deliberate anthrax infections in humans. The FDA may approve new drugs to thwart threats from biological warfare agents under the Bioterrorism Act of 2002.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next